Nicotine replacement therapies - NicoNovum AB

Drug Profile

Nicotine replacement therapies - NicoNovum AB

Alternative Names: NN Buccal 104; NN Explorer 203

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator NicoNovum AB
  • Class Alkaloids; Analgesics; Drug withdrawal therapies; Nicotine replacement therapy; Pyridines; Small molecules
  • Mechanism of Action Nicotinic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Clinical Phase Unknown Smoking withdrawal

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Smoking-withdrawal in Sweden (Buccal)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Smoking-withdrawal in Sweden (PO, Lozenge)
  • 05 May 2006 Clinical trials in Smoking withdrawal in Sweden (PO, gum 2mg)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top